Subscribe to Imaging
View Sample

FREE Email Newsletter

Stiefel Launches Most-Prescribed BPO Wash Formulations Over-the-Counter

February 4, 2011 9:36 am | by Bio-Medicine.Org | News | Comments

RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2011 /- Stiefel, a GSK company, today announced the launch of the most-prescribed BPO Acne Wash formulations for over-the-counter (OTC) use in the United States. The launch will occur in the technical exhibit at the American Academy of Dermatology...

58% of Physicians Support FDA Move to Pull Breast Cancer Indication from Avastin

February 4, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, Mass., Feb. 4, 2011 /- Sermo ( ), the world's largest online community for physicians, announced the publication of a free Sermo Report about how physicians are reacting to the FDA decision to rescind the indication for Avastin (bevacizumab) in the...

Photocure Announces Positive Allumeraâ„¢ Trial Results for Delivering Significant Skin Appearance Improvements

February 4, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

OSLO, Norway, Feb. 4, 2011 /- Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance....


MEDfx to Harmonize the Direct Project With CONNECT

February 4, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

WARWICK, R.I., Feb. 4, 2011 /- MEDfx Corporation today announced a Direct Project pilot that demonstrates health information exchange among providers using a combination of the standards and protocols supported by the Direct Project and the FHA CONNECT Gateway. MEDfx is participating in,...

FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors

February 4, 2011 12:34 am | by Bio-Medicine.Org | News | Comments

WAYNE, N.J., Feb. 4, 2011 /- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug...

Carrot Medical Reports 2010 Growth in Sales and Financing, Optimism for 2011

February 3, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

BOSTON, Feb. 3, 2011 /- Carrot Medical, a leading designer of integrated medical imaging display systems, has announced results for 2010. During the year, Carrot Medical achieved significant growth in sales, an expansion of sales channels and secured additional private financing. Carrot...

Curemark Hosts New York Senator Kirsten Gillibrand

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

RYE, N.Y., Feb. 3, 2011 /- Curemark, LLC , ( ), a drug research and development company focused on the treatment of neurological diseases, recently hosted New York Senator Kirsten Gillibrand as she announced a new proposal to spur innovation and job creation, locally and...

Hospira Announces FDA Approval of Topotecan Injection

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

LAKE FOREST, Ill., Feb. 3, 2011 /- Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United...


SkinMedica Launches Redness Relief CalmPlexâ„¢

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., Feb. 3, 2011 /- SkinMedica, Inc., the fastest-growing professional skin care company in the United States, today announced that it is introducing a new, fast-acting anti-redness product, Redness Relief CalmPlex™—the biggest innovation in redness in over two...

Dendreon Announces Exercise and Closing of Overallotment Option

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Feb. 3, 2011 /- Dendreon Corporation (Nasdaq: DNDN ) today announced that the underwriter in its previously announced public offering of 2.875% convertible senior notes due January 15, 2016 (the "Notes") exercised and closed on its overallotment option in full to purchase an...

Valeant Launches Senior Notes Offering

February 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, Feb. 3, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) (the "Company") announced today that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect subsidiary, launched its offer of approximately $650 million...

BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc.

February 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

NEWARK, N.J., Feb. 3, 2011 /- BioNeutral Group, Inc. (OTC Bulletin Board: BONU ), a specialty life science technology-based company, today announced the formation of BioNeutral Services, Inc., a wholly owned subsidiary of BioNeutral Group, Inc., and the appointment of Frank Battafarano as...

Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors

February 3, 2011 2:37 am | by Bio-Medicine.Org | News | Comments

MENLO PARK, Calif., Feb. 3, 2011 /- Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors.  Dr. Chaudhuri most recently served as President of...


Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B

February 2, 2011 10:36 pm | by Bio-Medicine.Org | News | Comments

GENEVA, Feb. 3, 2011 /- Inspiration Biopharmaceuticals, Inc. (Inspiration) today presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.  Results of the Phase 1...

Sonoma Orthopedic Products® Announces Key License and Distribution Agreement for Japan

February 2, 2011 7:36 am | by Bio-Medicine.Org | News | Comments

SANTA ROSA, Calif., Feb. 2, 2011 /- Sonoma Orthopedic Products announced that it has entered into a licensing and distribution agreement with Ai-Medic, a subsidiary of Olympus® Business Creation Corporation.  Ai-Medic is a leading supplier of orthopedic products in the Japanese...

Inovio Pharmaceuticals' Dual-Antigen SynConâ„¢ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial

February 2, 2011 1:35 am | by Bio-Medicine.Org | News | Comments

BLUE BELL, Pa., Feb. 2, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent...

Dawn Phillips Named as Vice President, Business Development for Catastrophic & Home Health Services

February 2, 2011 1:35 am | by Bio-Medicine.Org | News | Comments

JACKSONVILLE, Fla., Feb. 2, 2011 /- MSC, a leader in care management solutions serving post-injury workers' compensation patients announced today that Dawn Phillips has been named Vice President of Business Development for its Catastrophic & Home Health Services division....

Reportlinker Adds Pen Injectors

February 1, 2011 10:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Feb. 1, 2011 /- announces that a new market research report is available in its catalogue: Pen Injectors User-friendly designs and the availability of an increasing number of drugs in pre-filled disposable...

Inflammation Identified as New Therapeutic Target Years After Stroke

February 1, 2011 10:33 am | by Bio-Medicine.Org | News | Comments

LOS ANGELES, Feb. 1, 2011 /- A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting...

The 'Me-Covery': Saatchi & Saatchi Wellness and Time Inc.'s Health Brand Reveal Historic Shift in Female Consumer Behavior

February 1, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Feb. 1, 2011 /- American women are recovering from the economic crisis by prioritizing their own physical and emotional wellness in choices about their spending and brand selection, according to results from a new national consumer survey conducted by Saatchi & Saatchi...

Calling All 24/7 Moms! Ester-C - The Better Vitamin C, announces the launch of '24/7 Mom Contest'

February 1, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

BOHEMIA, N.Y., Feb. 1, 2011 /- Ester-C® is proud to announce the launch of the 24/7 Mom Contest, a contest designed to pay tribute to the unsung heroes in our lives – our moms. Do you know a mom who can juggle the house, the kids, scheduling, work and so much more? Then cast...

Canada's Windsor-Essex Region Collaborates With IBM to Improve Quality of Life for Citizens

February 1, 2011 4:35 am | by IBM | News | Comments

The region of Windsor-Essex, Ontario, Canada, today announced that it is using social business technology from IBM (NYSE: IBM) to significantly improve the quality of life for its citizens. E-mail this page Save to Digg this

PCMA: Ohio's Medicaid Program Could Save $135 Million

January 31, 2011 10:37 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Jan. 31, 2011 /PRNewswire-USNewswire/ -- Ohio's Medicaid program could cost taxpayers an additional $1.6 billion next year, a 49 percent jump in the state's share of costs for the health care program covering more than 2 million poor and disabled Ohioans, according to new...

New Interim Leadership for USP-Brazil

January 31, 2011 10:36 am | by Bio-Medicine.Org | News | Comments

ROCKVILLE, Md., Jan. 31, 2011 /PRNewswire-USNewswire/ -- To further its continuing partnerships with Brazilian public health authorities and pharmaceutical manufacturers, the U.S. Pharmacopeial Convention (USP) has appointed Mr. Nelson dos Santos as interim vice president of its Sao...

PDI to Present at the UBS 21st Annual Global Healthcare Services Conference

January 31, 2011 5:36 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J., Jan. 31, 2011 /- PDI, Inc. (Nasdaq: PDII ) today announced that Nancy Lurker, the company's chief executive officer, is scheduled to present at the UBS 21st Annual Global Healthcare Services Conference at 3:30 pm ET on February 8, 2011 at the Grand Hyatt New York. The...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.